论文部分内容阅读
目的观察伏立康唑治疗肾移植术后侵袭性肺曲霉菌病的临床疗效。方法入组10例临床诊断为侵袭性肺曲霉病(invasive pulmonary aspergil-losis,IPA)的肾移植术后患者,根据IDSA指南应用伏立康唑进行抗曲霉菌治疗,观察疗效及不良反应发生率,治疗结束后随访3个月。结果伏立康唑治疗肾移植术后IPA的有效率为70%,不良反应发生率为10%,未见严重不良反应,随访3个月内未见复发。结论伏立康唑是治疗肾移植术后IPA的有效治疗方法 。
Objective To observe the clinical efficacy of voriconazole in the treatment of invasive pulmonary aspergillosis after renal transplantation. Methods Ten patients with invasive pulmonary aspergillosis (IPA) were enrolled in this study. Patients were treated with voriconazole for anti-Aspergillus treatment according to IDSA guidelines. The efficacy and incidence of adverse reactions were observed and treatment was completed Follow-up 3 months. Results Voriconazole treatment of renal transplantation IPA effective rate was 70%, the incidence of adverse reactions was 10%, no serious adverse reactions, no recurrence within 3 months of follow-up. Conclusion Voriconazole is an effective treatment for IPA after renal transplantation.